Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Deals

Siyi Intelligence Raises Series A Funding for Neural Rehabilitation Solutions

Fineline Cube Mar 6, 2023

Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close...

Company Drug

Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA

Fineline Cube Mar 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the...

Company Drug

Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review

Fineline Cube Mar 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...

Company Drug

Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study

Fineline Cube Mar 6, 2023

China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully...

Company Deals

PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices

Fineline Cube Mar 6, 2023

PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...

Company Deals R&D

HKUST and PhIRDA Sign MoU to Establish Innovation Centers

Fineline Cube Mar 4, 2023

The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and...

Policy / Regulatory

China Releases Blue Book on Medical Insurance Fund Supervision

Fineline Cube Mar 3, 2023

The China Health Insurance and Social Sciences Academic Press has jointly released the “Blue Book...

Policy / Regulatory

NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines

Fineline Cube Mar 3, 2023

The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...

Company Deals

ClinChoice Acquires Cromsource to Expand Global CRO Footprint

Fineline Cube Mar 3, 2023

Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l.,...

Company Drug

Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment

Fineline Cube Mar 3, 2023

China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from...

Company Deals

Echo Biotech Secures Series A++ Funding for Exosomes Drug Development

Fineline Cube Mar 3, 2023

Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi...

Company Medical Device

AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL

Fineline Cube Mar 3, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion...

Company Drug

CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma

Fineline Cube Mar 3, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...

Policy / Regulatory

National VBP Tender Round 8 to Be Held in Hainan with 40 Drugs Bidding

Fineline Cube Mar 3, 2023

The National Allied Procurement Office has released a notification regarding the Round 8 of the...

Company Deals

TinKer Bio Raises Series A+ Funding for Microfluidic Chip Expansion

Fineline Cube Mar 3, 2023

China-based Hangzhou TinKer BioTechnology Co., Ltd, a leading microfluidic chip technology platform company, has reportedly...

Company Drug

OcuMension Therapeutics Initiates Phase II Study for Dry Eye Treatment OT-202

Fineline Cube Mar 3, 2023

Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the initiation of a randomized, double-blind,...

Company Deals

Hexin Medical Technology Raises Series A Funding for Radionuclide Therapy

Fineline Cube Mar 3, 2023

Hexin Medical Technology Co., Ltd, a radionuclide therapy developer based in Suzhou, has reportedly raised...

Company Deals

Shanghai Pharmaceuticals Partners with Baiyun District for Health Initiative

Fineline Cube Mar 3, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has entered into a strategic cooperation agreement...

Company Deals

TandemAI Secures $35M Series A to Expand Drug Discovery Platform

Fineline Cube Mar 3, 2023

TandemAI, a technology firm with operations in New York, San Diego, and China, has successfully...

Company Drug

Merck Reports 12.9% Sales Growth in 2022 Annual Report

Fineline Cube Mar 3, 2023

German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust...

Posts pagination

1 … 537 538 539 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.